SPRC$0.6218+4.05%
SciSparc Ltd.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: ILExchange: Nasdaq
Mkt Cap:$1.28M
Float & O/S:
Inst Own:
DilutionScan read 61 of SciSparc Ltd.'s SEC filings and found 7 warrant series, 2 convertibles, 1 ATM program, 1 equity line, 5 shelf registrations, 1 S-1 registration and 6 completed offerings on file for SPRC. The latest dilution event on file is an agreed share issuance on Oct 26, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
SPRC
Going-concern warning, severe cash distress
- Business
- WeakNet loss $12.2M vs $856K revenue, going-concern warning
- Stock risk
- High$1.4M micro-cap, reverse split, 2031% share growth, 117% dilution overhang
Snapshot
SciSparc is a clinical-stage cannabinoid drug developer with almost no revenue: $856K in FY2025, down 34.5% YoY, against a $12.2M net loss, meaning losses run over 14 times revenue.
What's Happening Right Now
- : SciSparc struck an inducement deal to convert $2.02M of convertible note principal and interest into shares at $1.50, adding roughly 1.35 million new shares with no cash to the company, closing around Oct 16, 2026.
- : SciSparc announced a shift toward Agentic AI, cybersecurity, and finance technology, saying no transaction or revenue-generating deal has yet been identified while its core business remains clinical-stage cannabinoid drug development.
- : A 6-K for the six months ended June 30, 2026 disclosed a $6.05M net loss on just $284K revenue, negative working capital of $1.4M, and explicit going-concern doubt with only $4.4M cash on hand.
- : An F-3/A registered resale of up to 2.56 million shares tied to a $2.0M convertible note and warrants, against only 580,973 shares outstanding at the time, a potential 5x increase in share count.
- : Subsidiary NeuroThera Labs closed a C$5.4M private placement, with SciSparc contributing C$2.7M for a stake it values at roughly C$30M, now holding about 44.6% of NeuroThera.
- : Registered 2.56M shares for sale on Form F-3.
- : Registered $50.00M of securities for sale on Form F-3.
- : Raised $1.80M in gross proceeds through a private placement (PIPE), with warrants over 406K shares and a $2.00M convertible note.
